Contents

Review Articles

419  Colistin: Revival of an Old Polymyxin Antibiotic
    Anneke C. Dijkmans, Erik B. Wilms, Ingrid M. C. Kamerling, Willem Birkhoff,
    Natalia V. Ortiz-Zacarias, Cees van Nieuwkoop, Henri A. Verbrugh, and Daan J. Touw

428  Clinical Practice Recommendations on Genetic Testing of CYP2C9
    and VKORC1 Variants in Warfarin Therapy
    Kaitlyn Shaw, Ursula Amstutz, Richard B. Kim, Lawrence J. Lesko, Jacques Turgeon,
    Veronique Michaud, Soomi Hwang, Shinya Ito, Colin Ross, and Bruce C. Carleton,
    the CPNDS Clinical Recommendation Group

Original Articles

437  Therapeutic Drug Monitoring of Levetiracetam and Lamotrigine: Is There a
    Need?
    Girish S. Naik, Rohit Kodagali, Binu S. Mathew, Maya Thomas, Ratna Prabha,
    Vivek Mathew, and Denise H. Fleming

445  A Multilaboratory Commutability Evaluation of Proficiency Testing Material
    for Carbamazepine and Valproic Acid: A Study Within the Framework of the
    Dutch Calibration 2000 Project
    Karen Robijns, Niels W. Boone, Aldy W. H. M. Kuypers, Rob T. P. Jansen, Cees Neef,
    and Daan J. Touw

(continued next page)
Contents (continued)

451 Detection Times of Diazepam, Clonazepam, and Alprazolam in Oral Fluid Collected From Patients Admitted to Detoxification, After High and Repeated Drug Intake
Kristin Nordal, Elisabeth L. Øiestad, Asle Enger, Asbjorg S. Christophersen, and Vigdis Vindenes

461 Prevalence of Therapeutic Drug Monitoring for Antidepressants and Antipsychotics in Stockholm, Sweden: A Longitudinal Analysis
Susanna M. Wallerstedt and Jonatan D. Lindh

466 Therapeutic Drug Monitoring of Lithium: A Study of the Accuracy and Analytical Variation Between Laboratories in Denmark
Tina Mose, Per Damkier, Magnus Petersen, and Steen Antonsen

472 LC–MS/MS Method for Determination of Teriflunomide, Over a 40,000-Fold Dynamic Range Using Overlapping Calibrators
Geoffrey S. Rule, Alan L. Rockwood, and Kamisha L. Johnson-Davis

479 Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays
Thomas Van Stappen, Els Brouwers, Sophie Tops, Nick Geukens, Séverine Vermeire, Paul J. Declerck, and Ann Gils

486 An Automated Homogeneous Immunoassay for Quantitating Imatinib Concentrations in Plasma
Jan H. Beumer, Daniel Kozo, Rebecca L. Harney, Caitlin N. Baldasano, Justin Jarrah, Susan M. Christner, Robert Parise, Irina Baburina, Jodi B. Courtney, and Salvatore J. Salamone

493 Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
Sara Bremer, Yngvar Floisand, Lorentz Brinch, Tobias Gedde-Dahl, and Stein Bergan

501 The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity

508 Therapeutic Drug Monitoring and Dose Adjustment of Posaconazole Oral Suspension in Adults With Acute Myeloid Leukemia
Shelly E. Hummert and Myke R. Green

(continued next page)
Contents (continued)

512 Roxithromycin Pharmacokinetics in Hospitalized Geriatric Patients: Oral Administration of Whole Versus Crushed Tablets
Malka Britzi, Matitiahu Berkovitch, Stefan Soback, Arthur Leibovitz, Rafael Segal, Marina Smagarinsky, and Emily Lubart

516 Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase
Xi Yao, Hongfeng Huang, Chunchun Wei, Ying Chen, Wenhan Peng, Wenzing Xie, and Jianguo Chen

524 Development of Limited Sampling Strategies for the Estimation of Tacrolimus Area Under the Curve in Adult Kidney Transplant Recipients According to the Posttransplantation Time
Karim Jouam, Zohra Chadli, Mouna Hammouda, Nadia Ben Fredj, Sabra Aloui, Mezri El May, Naceur Boughattas, Habib Skhiri, and Amel Chaabane

531 Methods for Predicting Warfarin Dose Requirements
Shamin M. Saffian, Daniel F. B. Wright, Rebecca L. Roberts, and Stephen B. Duffull

539 Determination of Ethyl Glucuronide in Hair for Detection of Alcohol Consumption in Patients After Liver Transplantation
Hilke Andresen-Streichert, Gregor von Rothkirch, Eik Vettorazzi, Alexander Mueller, Ansgar W. Lohse, Dorothea Frederking, Barbara Seegers, Bjoern Nashan, and Martina Sterneck

Short Communication

546 Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients
Monica Hermann, Ragnhild Birkeland Waade, and Espen Molden

Letters to the Editor

550 Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?
Etienne Brochot, Sandra Bodeau, and Gilles Duverlie

551 Key Elements in Determining Voriconazole Protein Binding Characteristics: Comment on “Determination of Plasma Unbound Fraction of Voriconazole in Patients Treated With a Prophylactic or a Curative Treatment”
Kim Vanstraelen, Steven Pauwels, Matthijs Oyaert, Johan Maertens, and Isabel Spriet

(continued next page)
Contents (continued)

Errata

554 Measuring Unbound Versus Total Vancomycin Concentrations in Serum and Plasma: Methodological Issues and Relevance
Veronique Stove

555 In Memoriam: Offie Soldin, PhD, MBA
Michael Oellerich and Gideon Koren

Conversion Formula

Readers who want to convert drug concentrations to or from SI units may apply the following formulas.

To determine the conversion factor (CF): \[ CF = \frac{1000}{MW} \]

To convert to SI units: \( (\mu g/mL) \times CF = (\mu mol/L) \)
To convert from SI units: \( (\mu mol/L) \div CF = (\mu g/mL) \)

Example: Phenytoin conversion

Conversion factor: \( CF = \frac{1000}{252.3} = 3.96 \)

Conversion: \( (\mu g/mL) \times 3.96 = (10 \mu g/mL) \times 3.96 = 39.6 \mu mol/L; \)
\( (39.6 \mu mol/L) \div 3.96 = 10 \mu g/mL \)